



SR1369

LRB100 19627 ALS 34900 r

1 SENATE RESOLUTION

2 WHEREAS, Eczema is a set of skin conditions that cause red,  
3 itchy, and inflamed skin, and has profound medical,  
4 psychosocial, and economic effects on patients, families, and  
5 their communities; and

6 WHEREAS, The prevalence of eczema in the United States is  
7 10.1 percent; and

8 WHEREAS, Eczema affects over 31.6 million children and  
9 adults in the United States alone; and

10 WHEREAS, Eczema's medical effects include dry, cracked,  
11 and scaly skin, incessant itch, chronic pain, and sleep  
12 deprivation; and

13 WHEREAS, 41.5 percent of adult eczema patients report  
14 having a co-occurring diagnosis of depression and 47.9 percent  
15 report having a co-occurring diagnosis of asthma; and

16 WHEREAS, Adults and children with eczema also frequently  
17 exhibit comorbidities like asthma, allergic rhinitis, food  
18 allergies, ADHD, bacterial and viral infections, and  
19 hypertension; and

1           WHEREAS, Eczema's disease burden also includes anxiety,  
2 stress on social and intimate relationships, increased  
3 suicidal ideation, delayed developmental achievement, reduced  
4 self-esteem, restrictions on diet and exercise, extensive  
5 caregiver burdens, and challenges with medication adherence;  
6 and

7           WHEREAS, Eczema results in missed days of school and work  
8 for patients and caregivers, disability, and reduced ability  
9 within a patient's chosen profession, unemployment and  
10 underemployment, and other opportunity costs; and

11           WHEREAS, The direct medical costs of the three most common  
12 types of eczema exceed \$2.17 billion, and the indirect medical  
13 costs exceed \$927 million; and

14           WHEREAS, Two-thirds of eczema patients report experiencing  
15 significant access barriers, including high out-of-pocket  
16 costs and insurance requirements that delay patients' access to  
17 medications; and

18           WHEREAS, There is no cure for eczema, but emerging  
19 technologies and medications promise a much brighter future for  
20 eczema patients; therefore, be it

21           RESOLVED, BY THE SENATE OF THE ONE HUNDREDTH GENERAL

1 ASSEMBLY OF THE STATE OF ILLINOIS, that the month of October  
2 2018 is designated as Eczema Awareness Month and residents are  
3 encourage to show support for Eczema Awareness.